Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute

Eur J Surg Oncol. 2011 Sep;37(9):805-10. doi: 10.1016/j.ejso.2011.06.009. Epub 2011 Jul 22.


Aims: The objective of this study was to investigate the clinical and oncological outcomes of prostatectomy patients undergoing minimum incision endoscopic radical prostatectomy (MIE-RP).

Methods: Between September 2005 and May 2010, 541 patients underwent MIE-RP with bilateral lymphadenectomy for clinically localized prostate cancer at Hirosaki University Hospital. The present retrospective study enrolled 375 patients who had not received neoadjuvant or adjuvant therapy. MIE-RP was performed through a 6-cm suprapubic midline incision. A 30° laparoscope was conveniently positioned on the head side of the patient for precise observation and monitoring.

Results: The median operating time was 119 min, and the estimated blood loss was 900 ml. The most frequent perioperative complication was leakage from the vesicourethral anastomosis (6.7%), and rectal injury occurred in 1.0%. Overall, 31.2% of the patients had a positive surgical margin, including 11.1% with pT2, 52.9% with pT3 and 100% with pT4 diseases. The post-operative median follow-up period was 40.5 months (range, 2-56.5 months). The 5-year PSA-free survival rate was 71.6%. In multivariate analysis, high-risk patients (according to the D'Amico risk criteria), pathological T stage and positive surgical margins were identified as independent predictors of PSA-free survival. The limitations of this study included a retrospective study, relatively short follow-up period and single-institution nature of the study.

Conclusions: MIE-RP is a safe and minimally invasive procedure that may represent a reliable alternative to laparoscopic and robotic-assisted RP.

MeSH terms

  • Aged
  • Disease-Free Survival
  • Endoscopy*
  • Humans
  • Laparoscopy
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Prostatectomy* / methods
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / surgery*
  • Robotics
  • Survival Rate